Please assess the completion status of the following clinical trial:

Trial Title: Treatment of West Nile Virus With MGAWN1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent~2. Be \>=18 years of age at the time of enrollment~3. Have West Nile Fever defined as:~   1. temperature \>38°C, headache, AND~  2. positive diagnostic test for WNV Ribonucleic acid or Immunoglobulin M with serum or cerebrospinal fluid (CSF)~   OR have West Nile Neuroinvasive Disease (includes neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis), defined as:~   • West Nile encephalitis (must meet criteria a and b below)~  1. Encephalopathy (depressed or altered level of consciousness, lethargy, or personality change lasting 24 hours)~  2. CSF pleocytosis \>=5 cells/mm\^3~      AND/OR~      • West Nile meningitis (must meet criteria c and d)~  3. Clinical signs of meningeal inflammation, including nuchal rigidity, Kernig or Brudzinski sign, photophobia, or phonophobia~  4. CSF pleocytosis \>=5 cells/mm\^3~      AND/OR~      • Acute flaccid paralysis (must meet criteria e and f)~  5. Acute onset of limb weakness with marked progression over 48 hours~  6. Two or more of the following conditions:~      * asymmetry to weakness~     * areflexia or hyporeflexia of affected limb(s)~     * absence of pain, paresthesia, or numbness in affected limb(s)~     * CSF pleocytosis \>=5 cells/mm\^3~     * CSF elevated protein levels (4.5 g/L)~     * electrodiagnostic studies consistent with an anterior horn cell process~     * or abnormal increased signal in the anterior gray matter as documented by spinal cord magnetic resonance imaging~4. Have epidemiological factors consistent with West Nile Virus infection (must meet criterion a or b below):~   1. Appropriate time of year for West Nile Virus transmission in region~  2. Travel history to a region where West Nile Virus is active~5. Develop signs and/or symptoms within 14 days before study enrollment.~6. If female of childbearing potential or male and in a sexual relationship with a female of childbearing potential, agree (or have partner agree) to practice abstinence or use 2 of the following methods of contraception for 120 days (approximately 4 months) after study drug administration:~   1. Oral contraceptives, or other form of hormonal birth control including hormonal vaginal rings or transdermal patches~  2. An intrauterine device~  3. Barrier contraception (condom) with a spermicide (i.e., female subject ensures use by male partner\[s\])~  4. Any other equivalent method of contraception (as judged by the investigator)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MGAWN1 (Type: EXPERIMENTAL): 30 mg/kg single intravenous infusion of MGAWN1
- Placebo - Normal Saline (Type: PLACEBO_COMPARATOR): single intravenous infusion of saline placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).